Search
V114 (15-valent pneumococcal conjugate vaccine [PCV]) contains all serotypes in 13-valent PCV (PCV13) and additional serotypes 22F and 33F. This study evaluated safety and immunogenicity of V114 compared with PCV13 in healthy infants, and concomitant administration with DTPa-HBV-IPV/Hib and rotavirus RV1 vaccines.
The current framework for testing and regulating vaccines was established before the realization that vaccines, in addition to their effect against the vaccine-specific disease, may also have "non-specific effects" affecting the risk of unrelated diseases. Accumulating evidence from epidemiological studies shows that vaccines in some situations can affect all-cause mortality and morbidity in ways that are not explained by the prevention of the vaccine-targeted disease.
Histo-blood group antigens (HBGAs) may influence immune responses to rotavirus vaccination.
This phase III study evaluated safety, tolerability, and immunogenicity of V114 (15-valent pneumococcal conjugate vaccine) in healthy infants. V114 contains all 13 serotypes in PCV13 and additional serotypes 22F and 33F.
A series of The Kids Research Institute Australia studies looking at safety for Meningococcal ACWY vaccines in children has led the way for its use in Australia.
Are you pregnant or planning to have a baby? There are important vaccinations that you should consider to protect your health and the health of your baby.
Consumers and community members are invited to join us to provide input into our childhood infectious diseases research.
We all know how important it is to vaccinate a child against harmful diseases but vaccinating a child at the right wrong age can cost lives.
A Kids Research Institute Australia researcher has been awarded $10,000 from the New Independent Researcher Infrastructure Support (NIRIS) award.
As a new parent or parent-to-be, you will be faced with many important decisions about your health and the health of your child, including immunisation.